electroCore (NASDAQ:ECOR) Issues Earnings Results, Misses Expectations By $0.05 EPS

electroCore (NASDAQ:ECOR) issued its quarterly earnings data on Wednesday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05), Fidelity Earnings reports. The company had revenue of $0.68 million during the quarter.

Shares of NASDAQ:ECOR traded up $0.10 on Friday, hitting $1.58. The company’s stock had a trading volume of 185,600 shares, compared to its average volume of 136,867. electroCore has a 1 year low of $1.23 and a 1 year high of $10.24. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.63 and a quick ratio of 5.93. The company has a 50-day simple moving average of $1.95 and a 200 day simple moving average of $2.42. The company has a market capitalization of $54.75 million, a PE ratio of -1.33 and a beta of 2.42.

A number of analysts recently issued reports on the company. BTIG Research reissued a “hold” rating on shares of electroCore in a report on Wednesday, August 14th. ValuEngine raised electroCore from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. JMP Securities cut electroCore from an “outperform” rating to a “market perform” rating in a report on Thursday. Noble Financial reaffirmed a “buy” rating and issued a $11.00 price target on shares of electroCore in a report on Thursday, August 15th. Finally, Zacks Investment Research cut electroCore from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $6.95.

electroCore Company Profile

electroCore, Inc, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Recommended Story: Why do companies issue monthly dividends?

Earnings History for electroCore (NASDAQ:ECOR)

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.